Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - B-Cell Lymphomas

Diagnosis and Treatment of Diffuse Large B-Cell Lymphomas (DLBCL)
DLBCL is now considered a heterogeneous group of distinct molecular subtypes characterized by substantially different clinical outcomes to standard chemoimmunotherapy.  New insights about the pathogenesis of DLBCL will eventually result in the development of more appropriately targeted therapies for the molecular subtypes of DLBCL. Accurate diagnosis with adequate immunophenotyping to identify the distinct molecular subtypes is the essential first step in the management of patients with DLBCL. Clinicians need to be educated about the recent advances that will lead to informed clinical decisions for individual patients and help clinicians incorporate these findings more effectively into their clinical management of patients with DLBCL.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the molecular heterogeneity of DLBCL and its implications in the management of patients with DLBCL.
  • Summarize the current options for the treatment of newly diagnosed DLBCL and discuss the evidence from clinical trials on the use of novel therapeutic strategies. 
  • Develop a treatment plan that integrates novel treatment options for the management of patients with relapsed/refractory DLBCL.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer U.S. LLC
  • Celgene Corporation
  • Clovis Oncology
  • Eisai
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Taiho Oncology

This activity is supported by an independent educational grant from TESARO.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.85 ANCC contact hours
  • 0.75 Participation
Course opens: 
06/06/2019
Course expires: 
06/06/2020
Cost:
$0.00

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Jason T. Carter, PA-C, MPH
Memorial Sloan Kettering Cancer Center

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Jason T. Carter, PA-C, MPH

The faculty listed below discloses the following relevant financial relationships:
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Scientific Advisor; Consulting Fee
Adaptive Biotechnologies Corporation: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Scientific Advisor; Consulting Fee
BeiGene: Grant/Research Support; Other Financial Benefit
Celgene Corporation: Consulting Fee
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support; Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc: Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pharmacyclics: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Sarah Sinclair; Kathy Ann Smith, CHCP

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.85 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-062-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until 6/6/2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.85 ANCC contact hours
  • 0.75 Participation

Accreditation Period

Course opens: 
06/06/2019
Course expires: 
06/06/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing